Amgen (AMGN) Competitors

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

In the previous week, Amgen and Amgen both had 40 articles in the media. Amgen's average media sentiment score of 0.70 beat Moderna's score of 0.23 indicating that Amgen is being referred to more favorably in the media.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amgen has a net margin of 22.95% compared to Moderna's net margin of -141.43%. Amgen's return on equity of 124.14% beat Moderna's return on equity.

Amgen presently has a consensus price target of $383.46, indicating a potential downside of 5.56%. Moderna has a consensus price target of $76.72, indicating a potential downside of 60.62%. Given Amgen's stronger consensus rating and higher probable upside, equities analysts plainly believe Amgen is more favorable than Moderna.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amgen had 16 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 40 mentions for Amgen and 24 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.78 beat Amgen's score of 0.70 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat Vertex Pharmaceuticals' return on equity.

Amgen has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Amgen currently has a consensus target price of $383.46, indicating a potential downside of 5.56%. Vertex Pharmaceuticals has a consensus target price of $573.83, indicating a potential upside of 9.85%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

76.5% of Amgen shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Amgen currently has a consensus target price of $383.46, suggesting a potential downside of 5.56%. AbbVie has a consensus target price of $276.64, suggesting a potential upside of 4.38%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Amgen.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

In the previous week, Amgen had 1 more articles in the media than AbbVie. MarketBeat recorded 40 mentions for Amgen and 39 mentions for AbbVie. Amgen's average media sentiment score of 0.70 beat AbbVie's score of 0.61 indicating that Amgen is being referred to more favorably in the media.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.5%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Amgen has a net margin of 22.95% compared to Astrazeneca's net margin of 17.02%. Amgen's return on equity of 124.14% beat Astrazeneca's return on equity.

Astrazeneca currently has a consensus price target of $206.67, suggesting a potential upside of 25.60%. Amgen has a consensus price target of $383.46, suggesting a potential downside of 5.56%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Astrazeneca has higher revenue and earnings than Amgen. Astrazeneca is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.5%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Amgen pays out 62.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Astrazeneca has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

In the previous week, Amgen had 21 more articles in the media than Astrazeneca. MarketBeat recorded 40 mentions for Amgen and 19 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.90 beat Amgen's score of 0.70 indicating that Astrazeneca is being referred to more favorably in the media.